



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Christopher E. M. Griffiths
✉ Christopher.Griffiths@manchester.ac.uk

SPECIALTY SECTION
This article was submitted to
Dermatology,
a section of the journal
Frontiers in Medicine

RECEIVED 21 February 2023
ACCEPTED 22 February 2023
PUBLISHED 10 March 2023

CITATION
Egeberg A, Merola JF, Schäkel K, Puig L,
Mahar PD, Wang IY, Pavo I, Schuster C and
Griffiths CEM (2023) Corrigendum: Efficacy of
ixekizumab in patients with
moderate-to-severe plaque psoriasis and
prediabetes or type 2 diabetes.
Front. Med. 10:1171132.
doi: 10.3389/fmed.2023.1171132

COPYRIGHT
© 2023 Egeberg, Merola, Schäkel, Puig, Mahar,
Wang, Pavo, Schuster and Griffiths. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted which
does not comply with these terms.

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg¹, Joseph F. Merola², Knut Schäkel³, Luis Puig⁴,
Patrick D. Mahar^{5,6}, Isabella Yali Wang⁵, Imre Pavo⁵,
Christopher Schuster^{5,7} and Christopher E. M. Griffiths^{8*}

¹Bispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark, ²Division of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States, ³Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany, ⁴Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, United States, ⁶Department of Dermatology, Royal Children's Hospital, Faculty of Medicine, Nursing and Health Sciences, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia, ⁷Department of Dermatology, Medical University of Vienna, Vienna, Austria, ⁸Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom

KEYWORDS

moderate-to-severe psoriasis, type 2 diabetes, prediabetes, ixekizumab, obesity

A corrigendum on

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

by Egeberg, A., Merola, J. F., Schäkel, K., Puig, L., Mahar, P. D., Wang, I. Y., Pavo, I., Schuster, C., and Griffiths, C. E. M. (2023). *Front. Med.* 9:1092688. doi: 10.3389/fmed.2022.1092688

In the published article, there was an error regarding the Conflict of Interest for Patrick D. Mahar, Christopher Schuster, Imre Pavo, and Isabella Yali Wang. The Conflict of Interest statement should be:

AE has honoraria as consultant and/or speaker from AbbVie, Ammirall, Bristol-Meyers Squibb, Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. LP has received honoraria/consultation fees from Abbvie, Ammirall, Amgen, Baxalta, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB. LP has participated in company sponsored speaker's bureau for Celgene, Janssen, Lilly, MSD, Novartis and Pfizer. KS is a consultant, investigator, speaker and has received grants from: AbbVie, Amgen, Ammirall, Biogen, Bristol-Myers Squibb Boehringer Ingelheim, Celgene, Chugai, Galderma, Janssen-Cilag, Leo-Pharma, Lilly, Merck Sharp & Dohme Corp., Morphosys, Novartis, Pfizer, Regeneron, UCB Pharma. JM is a consultant and/or investigator for Amgen, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. CG has received honoraria or research grants from AbbVie, Ammirall, Anaptysbio Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Pfizer, Novartis, ONO Pharmaceuticals, UCB Pharma and Walgreens Boots Alliance, and is supported in part by the Manchester NIHR Biomedical Research Centre. PM has served as

a consultant, investigator, speaker and/or advisor for Novartis, AstraZeneca, Abbvie, Pfizer, Bristol-Meyers Squibb, Eli Lilly and Company and Boehringer Ingelheim. PM, CS, IP, and IW are employees of Eli Lilly and Company. PM owns equity in Eli Lilly and Company. CS, IP, and IW are minor shareholders of Eli Lilly and Company.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.